{"schema_version":"secwatch.filing_event.v1","accession":"0001490978-23-000108","form_type":"8-K","ticker":"SDGR","cik":"0001490978","company_name":"Schrodinger, Inc.","filed_at":"2023-11-01T23:59:59+00:00","discovered_at":"2026-05-14T18:03:29.229640+00:00","generated_at":"2026-06-09T02:26:06.682391+00:00","sec_items":["2.02","9.01"],"event_type":"earnings","sentiment":"negative","materiality_score":0.8,"calibrated_materiality_score":0.8,"confidence":"high","headline":"Schrödinger Q3 revenue $42.6M (+15% YoY); net loss widens to $62M; updates guidance","bullets":["Total revenue $42.6M (+15% YoY); software revenue $28.9M (+17%); drug discovery $13.7M (+11%).","Net loss $62.0M vs $39.9M in Q3 2022; operating expenses rose 26% to $79.8M.","Updated FY2023 guidance: software revenue growth 15-18%; drug discovery $50-70M; cash from ops expected higher.","Pipeline: SGR-1505 healthy volunteer data due Q4; SGR-2921 Phase 1 started; PRMT5-MTA program disclosed.","Bristol Myers Squibb returned rights to two oncology programs; company maintains ~$503M cash."],"urls":{"canonical":"https://secwatch.observer/filing/0001490978-23-000108","json":"https://secwatch.observer/filing/0001490978-23-000108.json","markdown":"https://secwatch.observer/filing/0001490978-23-000108.md","text":"https://secwatch.observer/filing/0001490978-23-000108.txt","edgar_index":"https://www.sec.gov/Archives/edgar/data/1490978/000149097823000108/0001490978-23-000108-index.htm","edgar_primary_document":"https://www.sec.gov/Archives/edgar/data/1490978/000149097823000108/sdgr-20231101.htm"},"model":{"generated_by":"deepseek-v4-flash:cloud@v2","generated_at":"2026-06-09T02:26:06.682391+00:00"},"review":{"review_status":"machine_generated","human_reviewed":false,"corrected":false,"correction_note":null,"correction_timestamp":null,"superseded_by":null,"related_filings":[]},"source_grounded_claims":[{"claim_id":"2b0e4f4fab28c87d53b1d7b6be64b7caab372e6a","claim":"Schrodinger, Inc. reported the third quarter ended September 30, 2023 results: revenue $42.6 million, net income $71.4 million. Guidance reaffirmed.","evidence_excerpt":"incorporated by specific reference in such filing. --- EX-99.1 (EX-99.1) --- Schrödinger Reports Third Quarter 2023 Financial Results Delivers Third Quarter Total Revenue of $42.6 Million; Maintains Full-Year 2023 Revenue Guidance Continued Progress for SGR-1505, Healthy Volunteer Data Expected in Fourth Quarter of 2023 Phase 1 Study Initiated for SGR-2921;","evidence_source":"SEC 8-K Item 2.02","evidence_url":"https://www.sec.gov/Archives/edgar/data/1490978/000149097823000108/0001490978-23-000108-index.htm","confidence":0.9,"family_label":"Earnings Releases","details":[{"label":"Period","value":"the third quarter ended September 30, 2023"},{"label":"Revenue","value":"$42.6 million"},{"label":"Net income","value":"$71.4 million"},{"label":"Guidance","value":"reaffirmed"},{"label":"Result","value":"reported results"}],"fact_type":"earnings_release"}],"license":"Source filings: public domain (SEC EDGAR). Summaries (headline + bullets): CC-BY-4.0; attribute https://secwatch.observer"}